Earnings call transcript: Santhera H1 2026 meets forecasts as sales surge

Santhera's H1 2026 revenue more than doubled year over year to CHF 48.3 million, while its operating loss narrowed sharply to CHF 6.6 million from CHF 35.4 million. Growth was led by 48% higher direct and distributor product sales for DMD drug AGAMREE and CHF 29.1 million in royalties and milestones, including Nxera's $30 million upfront licensing payment. The company reaffirmed CHF 80 million-CHF 90 million of 2026 revenue guidance, but expects an 8.5% German pricing discount and inventory timing to reduce cash in H1 2027 before a return to cash generation in H2 2027.

Analysis

The earnings quality is weaker than the headline growth implies: non-recurring licensing consideration and milestone-related accounting obscure the underlying commercial run-rate, while a sizeable partner payment booked in cost of sales depresses reported gross margin. More importantly, royalties from the largest partner channels are being directed to royalty-finance providers until repayment, so “underlying” operating cash positivity is not equivalent to freely available equity cash flow. The market is likely to refocus on the H1 2027 cash trough rather than the unchanged near-term revenue range.

SANN’s equity case rests on volume compounding fast enough to offset a German net-price reset and the loss of one-time licensing income. The near-term catalyst path is market-access conversion in Spain/Italy and a LATAM partnership over the next 1-3 months; the more material 6-18 month rerating catalysts are U.S. partner sales acceleration, Chinese reimbursement progress, Japanese filing, and the next long-term data update. Conversely, delayed regional access, any slowdown in switching from legacy steroids, or cash falling below management’s implied funding-free runway would force dilution concerns and multiple compression.

The non-obvious beneficiary is NEXR: successful Japanese development would turn its upfront investment into strategic optionality across multiple inflammatory indications, but this is a long-duration, execution-heavy thesis rather than a read-through to near-term earnings. Contrarian view: SANN may be underappreciated if its direct European platform can support a second commercial asset with limited incremental opex; however, management’s stated in-licensing ambition introduces capital-allocation risk precisely before the projected cash trough, making a premium acquisition or equity-funded deal the key downside scenario.

Key Decisions for Investors

• Watch-list SANN for a tactical long only after confirmation that H2 product-sales growth—not licensing income—supports the full-year range. Target a 6-12 month hold into 2027 clinical/commercial catalysts; invalidate if cash guidance implies external financing or if direct-market growth falls materially below the company’s >50% annual target.
• Do not chase the post-results move: require evidence from the next update that Spain/Italy regional access is translating into paid prescriptions and that German volume growth offsets the 2027 net-price reduction. Size modestly given single-asset, small-cap liquidity and partner-concentration risk.
• Use CPRX/Angelini-linked U.S. sales disclosures as the highest-frequency read-through for SANN’s royalty economics. A sustained deceleration in U.S. net sales or adverse changes in commercial investment should trigger a reduction in any SANN exposure before the H1 2027 cash draw.
• Maintain NEXR as a separate, longer-dated optionality watch item rather than a paired trade: Japanese regulatory filing progress and formal indication-expansion plans are the relevant catalysts, while development spend and regulatory timing limit near-term risk/reward visibility.